peptide similar to semaglutide Tirzepatide vs. Semaglutide: Key Differences in Metabolic Research 99.00 | Semaglutide with B-12
Description
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024
The yerba mate market size is projected to grow from $2.29 billion in 2026 to $3.58 billion by 2034, at a CAGR of 5.72% during the forecast period 2026-2034.

GLP-1s Make Weight Loss Easier And More Attainable Now
